Available online on 15.05.2017 at http://jddtonline.info

Journal of Drug Delivery and Therapeutics
Open access to Pharmaceutical and Medical research

Mini Review

CANCER THERAPY WITH CO-DELIVERY OF CAMPTOTHECIN

Shuosheng Zhang*

College of traditional Chinese medicine, Shanxi University of Traditional Chinese Medicine, No. 121 of University Street, 030619, Jinzhong, Shanxi, China

Article Info: Received 25 April 2017; Review Completed 07 May 2017; Accepted 07 May 2017, Available online 15 May 2017

Cite this article as:

Zhang S, Cancer therapy with co-delivery of Camptothecin, Journal of Drug Delivery and Therapeutics. 2017; 7(3):76-79

DOI: http://dx.doi.org/10.22270/jddt.v7i3.1450

***Address for Correspondence:**

Shuosheng Zhang, College of traditional Chinese medicine, Shanxi University of Traditional Chinese Medicine, No. 121 of University Street, 030619, Jinzhong, Shanxi, China,
E-mail address: zhangshuosheng@aliyun.com

ABSTRACT

This essay has discussed various ways by which two or more than two drugs have been combined with Camptothecin through nanoparticles in order to yield anti-cancer therapy effectiveness. A systematic and comprehensive literature review has been prepared to show such combinations demonstrated high anticancer efficacy.

Keywords: Combination drug therapy, Camptothecin, pharmaceutics

INTRODUCTION

Camptothecin, (CPT) as well as its various analogues, is regarded as anticancer drugs of most promising nature.[1-3] The drugs are such that they result in targeting the topoisomerase which is a nuclear enzyme. [4,5] CPTs, however, are problems to be clinically applied.[6] This is because they do not have adequate solubility in water and are not stable when PH is neutral. This results in deactivating CPTs through conversion of CPT from its lactone form to its form of carboxylate.[7-9] This is possible by combining CPT with other drugs that assist CPT to deal with its drawbacks.[10-12] This paper takes into consideration the various combination components that can be used to combine with CPTs in order to prove their effectiveness as anti-cancer drugs.[13-15] This is done by regarded various literature articles popular in the field.

Camptothecin + Doxorubicin via Folding graft copolymer

According to the article by Wanyi Tai et al.[16], folding into nanostructures is possible with pendant drug segments and graft copolymer. In order to construct a graft copolymer, polymerization of ŷ-camptothecin-glutamate N-carboxy anhydride over several poly-ethylene glycol sites is done. This is dependent upon the key chain through the polymerization process of ring open). The CPT or the camptothecin in this situation is an agent of anti-cancer with simple conjugation. The nature of such a CPT is hydrophobic in nature.[17,18] It serves as the key dynamic force throughout the process of folding. When exposure of this comes in with water, the copolymer is gained.[19] Doxorubicin then results in being folded into nanocarriers which can be monodispersed for delivery of the dual drug. Good stability is depicted by the nano-carriers as they have proper PEG shell equipment. The nano-carriers could be internalized through several cell lines of cancer through the endocytic pathway mediated through clathrin and lipid raft without the leakage of premature nature. [20] This depicted a higher CPT based synergetic activity as well as Dox in the direction of several cells of cancer. The article further showed the validation through "in vivo" study exhibiting an accumulation of strong nature within the sites of tumor. It went on to show an activity of anti-cancer prominently in the opposite xenograft

with the model of xenograft mice in comparison to free drugs.

Camptothecin + Doxorubicin via Supramolecular Hydrogel

According to the article by Zhang et al.[21], another method has been explored for sustaining therapy of synergistic tumor. The article states that multiple drugs co-delivery has become the key strategy for the therapy of cancer in the recent times.[22,23] This is because the process can lead towards promoting actions of synergistic nature. The process also results in reducing any side influences and deters drug resistance development. For achieving loaded drugs controlled and sustained release, the hydrogel of supramolecule base is taken on the basis of interactions between host and guest.[24,25] The interactions take place between derivatives of polyglycerol hyper-branching as well as alpha-cyclodextrin. The alpha-cyclodextrin preparation was done and it was utilized for co-loading the camptothecin as well as doxorubicin for sustaining the therapy of synergistic tumor. The kinetics of gelation, the strength of hydrogel as well as the obtained hydrogel supra-molecular structure were taken into consideration. This was done through the process of rheometry which was both dynamic and steady under several alpha CD concentrations. The supramolecular hydrogel leads towards releasing dual drug sustainability. This is shown in the article through in-vitro studies. The exploration was done in the article for their synergistic influences in vivo and vitro. The supramolecular hydrogel depicted compatibility of receivable blood and non-cytotoxicity through the assays of in vitro and in vivo. It was clear that sustaining tumor therapy synergistic is possible through the supra-molecule hydrogel.

Camptothecin and curcumin by cationic polymeric nanoparticles

In the article by Xiao et al.[26], another potent strategy has been explored. In this strategy, the chemotherapy process is done using combination based on nanoparticles to enhance concentrations of the drug intracellularly. This allows for the achievement of synergistic influences within the therapy of colon cancer. In this, fabrication was done of several CPTs with chitosan functionalization.[27] This illustrated various CPT and CUR ratios. The result was a CPT with the cationic sphere with a desired size of the particle at 193 to 224 nm. This had a relatively distributed small size and slight zeta potential positivity. Such nanoparticles depicted a sustainability of simultaneous nature with releasing profile for the drugs across the period of research with the light release of the first burst. Experiments subsequently with the uptake of cells depicted through chitosan introduction to the surface of NP-led towards increasing the efficiency of cellular uptake in comparison with the formulation of other drugs. This, therefore, enhanced the synergistic influences from the drugs. The testing of 5 cationic CPTs was done. CPTs with nanoparticles had a weighing ratio with 4:1. This depicted the highest activity of anti-cancer. This resulted in an index of combined nature at 0.46. The study represented the initial report of combined CPT and CUR application with initial step fabrication system consisting of co-delivery. This was done for the effectiveness of combined chemotherapy for colon cancer.

Co-delivery of 10-Hydroxycamptothecin with Doxorubicin Conjugated Prodrugs

In the article by Zhang et al.[28], properly defined prodrugs with amphiphilic linear- dendritic synthesis are done. This is done by doxorubicin conjugation towards MPEG-b-PAMAM by the hydrazine bond of acid-labile.[29]The prodrugs with amphiphilic nature for nano-particles of the self-assembled form are used. This happens in water with deionization. This results in encapsulating the anticancer drug having a hydrophobic nature. The drug is namely 10-hydroxycamptothecing with the efficiency of higher drug loading. Drug release and cell uptake studies of the system of co-delivery depicted that these drugs get released in a manner that is dependent on pH. They are taken up effectively through the cells of MCF-7. Nanoparticles loaded with HCPT result in suppressing the growth of cancer cells in a much efficient manner than the prodrugs named, MPEG-bPAMAM-DOX. HCPT loaded nano-cells are better than free HCPT, MPEG-b-PAMAM-DOX physical mixtures as well as HCPT with DOX equivalence. This has been demonstrated in the article through in-vitro assay apoptosis tests in which drugs namely methyl thiazolyl tetrazolium, were induced. The article reports that nanoparticles based on polymers can result in facilitation for solving the solubility issue of CPTs and for protecting these from degrading prematurely.

The article takes into consideration that studies have shown not to make use of individual drugs for chemotherapeutics. These drugs have no efficiency and several limitations when viewing them to treat cancers. The restrictions are inclusive of drug resistance development, high toxic level and limited clinical usage regime.[30,31] Nanocarriers with pH sensitivity have mostly gained more attention since distinct levels of pH are exhibited by the tumor in comparison to tissues which are healthy. In the situation where polymer-drugs are involved, conjugation is formed through co-polymer amphiphilic blocks. These are known as pro-drug polymeric. This is the responsive component.

A Convergent Synthetic Platform for combination delivery of Cisplatin, Doxorubicin, and Camptothecin

As per the article by Liao et al.[32], another potential combination for therapy of cancer has been offered. The article states that combined therapy of cancer with basis on nano-particle can overcome traditional systemic therapies toxic and poor control. Therefore, the article offers a solution. It states that polymer therapeutics synthesis with control load capability and capacity of multiple therapeutic agents' synchronized release is a key challenge. It is not only a challenge for delivery of the drug, but also for the chemistry of synthetic polymer. In the article, the authors have reported polymer based nanoparticles synthesis. These particles carry specific doxorubicin molar ratios, cisplatin, and

camptothecin. The article has provided an initial example for three drugs orthogonal trigger release from individual nanoparticles. The approach of great convergence synthetics opens a pathway for new combinational therapies based on NP as anti-cancer drugs. [33]

A cross-link design was taken in this article where more focus was on derivatives of diester with Pt (IV). These were applied widely in the form of pro-drugs for chemotherapeutic cisplatin clinical approval. Kinetics is then released to help enhance the effectiveness of the procedure. The selection was based on specific tests confirming the usage as well as application.

CONCLUSION

This is to conclude that nanoparticles have the ability to serve as anti-cancer drugs with efficiency. However, without combining them with other particles, this is not possible. When two or more than two drugs are combined, it results in promoting synergistic effects between distinct drugs in opposition to cells of cancer. It also results in suppressing the resistance of drugs by different action mechanisms. Delivery of nanoparticle drugs, on the contrary, helps in enhancing the effectiveness of therapy and reducing drug payloads side effects through pharmacokinetics. This paper has summarized recently combined therapies proposed for anti-cancer drugs efficiency and the therapy of cancer efficiently.

REFERENCES

1. Hsiang Y-H, Hertzberg R, Hecht S, and Liu L. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. *Journal of Biological Chemistry*. 1985, **260**: 14873-14878
2. Cheng X. Developing organic and inorganic nanomedicine for cancer therapy. *Journal of Drug Delivery and Therapeutics*. 2017, **7(3)**:1-4 DOI: 10.22270/jddt.v7i2.1367
3. Cheng X, and Lee R J. The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery. *Adv Drug Deliv Rev*. 2016, **99**: 129-137; doi: 10.1016/j.addr.2016.01.022.
4. Liu F, Sun Y, Kang C, and Zhu H. Pegylated Drug Delivery Systems: From Design to Biomedical Applications. *Nano LIFE*. 2016, **6**: 1642002
5. Cheng X, Liu Q, Li H, Kang C, Liu Y, Guo T, et al. Lipid Nanoparticles Loaded with an Antisense Oligonucleotide Gapmer Against Bcl-2 for Treatment of Lung Cancer. *Pharm Res*. 2017, **34**: 310-320; doi: 10.1007/s11095-016-2063-5.
6. Li Q-Y, Zu Y-G, Shi R-Z, and Yao L-P. Review camptothecin: current perspectives. *Current medicinal chemistry*. 2006, **13**: 2021-2039
7. Sriram D, Yogeeswari P, Thirumurugan R, and Ratan Bal T. Camptothecin and its analogues: a review on their chemotherapeutic potential. *Natural product research*. 2005, **19**: 393-412
8. Li H, Cheng X, Liu Y, Lee Y B, Kim D J, Ahn C-h, et al. Folate receptor-targeted lipid coated albumin nanoparticles (F-LCAN) for therapeutic delivery of RX-0201 (Archexin®), an antisense oligonucleotide against Akt-1. 2016,
9. Li H, Quan J, Zhang M, Yung B C, Cheng X, Liu Y, et al. Lipid-Albumin Nanoparticles (LAN) for Therapeutic Delivery of Antisense Oligonucleotide against HIF-1alpha. *Mol Pharm*. 2016, **13**: 2555-2562; doi: 10.1021/acs.molpharmaceut.6b00363.
10. Kang C, Sun Y, Wang M, and Cheng X. Nanosized camptothecin conjugates for single and combined drug delivery. *European Journal of BioMedical Research*. 2016, **2**: 8-14
11. Kang C, Sun Y, Zhu J, Li W, Zhang A, Kuang T, et al. Delivery of Nanoparticles for Treatment of Brain Tumor. *Current Drug Metabolism*. 2016, **17**: 745-754
12. Sun Y, Kang C, Liu F, and Song L. Delivery of Antipsychotics with Nanoparticles. *Drug Development Research*. 2016, **77**: 393-399
13. Sun Y, Kang C, Zhang A, Liu F, Hu J, Zhong X, et al. Co-delivery of dual-drugs with nanoparticle to overcome multidrug resistance. *European Journal of BioMedical Research*. 2016, **2**: 12-18
14. Duan Y, Pei K, Cai H, Tu S, Cheng X, Zhang Z, et al. Strategy of integrated evaluation on treatment of traditional Chinese medicine as 'interaction of system to system'and establishment of novel fuzzy target contribution recognition with herb-pairs, a case study on Astragali Radix-Fructus Corni. *Molecular and Cellular Endocrinology*. 2016, **434**: 219-237
15. Duan Y, Pei K, Cai H, Tu S, Zhang Z, Cheng X, et al. Bioactivity evaluation-based ultra high-performance liquid chromatography coupled with electrospray ionization tandem quadrupole-time-of-flight mass spectrometry and novel distinction of multi-subchemome compatibility recognition strategy with Astragali Radix-Fructus Corni herb-pair as a case study. *Journal of pharmaceutical and biomedical analysis*. 2016, **129**: 514-534
16. Tai W, Mo R, Lu Y, Jiang T, and Gu Z. Folding graft copolymer with pendant drug segments for co-delivery of anticancer drugs. *Biomaterials*. 2014, **35**: 7194-7203; doi: 10.1016/j.biomaterials.2014.05.004.
17. Chen Y, Bian Y, Sun Y, Kang C, Yu S, Fu T, et al. Identification of 4-aminoquinoline core for the design of new cholinesterase inhibitors. *PeerJ*. 2016, **4**: e2140
18. Han R, Sun Y, Kang C, Sun H, and Wei W. Amphiphilic dendritic nanomicelle-mediated co-delivery of 5-fluorouracil and doxorubicin for enhanced therapeutic efficacy. *Journal of Drug Targeting*. 2017, **25**: 140-148
19. Sun Y, Kang C, Yao Z, Liu F, and Zhou Y. Peptide-Based Ligand for Active Delivery of Liposomal Doxorubicin. *Nano LIFE*. 2016, **6**: 1642004
20. Kang C, Qin J, Osei W, and Hu K. Regulation of protein kinase C-epsilon and its age-dependence. *Biochemical and Biophysical Research Communications*. 2017, **482**: 1201-1206
21. Zhang W, Zhou X, Liu T, Ma D, and Xue W. Supramolecular hydrogels co-loaded with camptothecin and doxorubicin for sustainedly synergistic tumor therapy. *Journal of Materials Chemistry B*. 2015, **3**: 2127-2136
22. Qiao H, Fang D, Chen J, Sun Y, Kang C, Di L, et al. Orally delivered polycurcumin responsive to bacterial reduction for targeted therapy of inflammatory bowel disease. *Drug Delivery*. 2017, **24**: 233-242
23. Sun Y, and Kang C. Self-Assembly of Peptides into Hydrogel. *Journal of Organic & Inorganic Chemistry*. 2016,

24. Song L, Kang C, Sun Y, Huang W, Liu W, and Qian Z. Crocetin Inhibits Lipopolysaccharide-Induced Inflammatory Response in Human Umbilical Vein Endothelial Cells. *Cellular Physiology and Biochemistry*. 2016, **40**: 443-452

25. Waller A P, George M, Kalyanasundaram A, Kang C, Periasamy M, Hu K, et al. GLUT12 functions as a basal and insulin-independent glucose transporter in the heart. *Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease*. 2013, **1832**: 121-127

26. Xiao B, Si X, Han M K, Viennois E, Zhang M, and Merlin D. Co-delivery of camptothecin and curcumin by cationic polymeric nanoparticles for synergistic colon cancer combination chemotherapy. *Journal of Materials Chemistry B*. 2015, **3**: 7724-7733

27. XU S-h, Chen K, CHEN M-l, ZHOU P-p, HE G-w, CUI Y-j, et al. Dynamic expression of AQP4 in early stageof ischemia/reperfusion rats and cerebral edema. *Chinese Pharmacological Bulletin*. 2016: 1433-1441

28. Zhang Y, Xiao C, Li M, Chen J, Ding J, He C, et al. Co-delivery of 10-Hydroxycamptothecin with Doxorubicin Conjugated Prodrugs for Enhanced Anticancer Efficacy. *Macromolecular bioscience*. 2013, **13**: 584-594

29. Xue X, Zhao N-Y, Yu H-T, Sun Y, Kang C, Huang Q-B, et al. Discovery of novel inhibitors disrupting HIF-1α/von Hippel–Lindau interaction through shape-based screening and cascade docking. *PeerJ*. 2016, **4**: e2757

30. Yang Z, Xie J, Zhu J, Kang C, Chiang C, Wang X, et al. Functional exosome-mimic for delivery of siRNA to cancer: in vitro and in vivo evaluation. *Journal of Controlled Release*. 2016, **243**: 160-171

31. Yao Z, Sun Y, and Kang C. Structure and Self-Assembly of Multicolored Naphthalene Diimides Semiconductor. *Nano LIFE*. 2016, **6**: 1642007

32. Liao L, Liu J, Dreaden E C, Morton S W, Shopsowitz K E, Hammond P T, et al. A convergent synthetic platform for single-nanoparticle combination cancer therapy: ratiometric loading and controlled release of cisplatin, doxorubicin, and camptothecin. *Journal of the American Chemical Society*. 2014, **136**: 5896

33. Zhong X, Sun Y, Kang C, and Wan G. The theory of dielectrophoresis and its applications on medical and materials research. *European Journal of BioMedical Research*. 2017, **2**: 7-11